{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T18:15:16Z","timestamp":1788372916632,"version":"build-2803163510"},"reference-count":15,"publisher":"Georg Thieme Verlag KG","issue":"03","license":[{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"vor","delay-in-days":1062,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2019,4,20]],"date-time":"2019-04-20T00:00:00Z","timestamp":1555718400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["e-aps.org"],"crossmark-restriction":true},"short-container-title":["Arch Plast Surg"],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:p>Hidradenitis suppurativa (HS) is a chronic inflammatory follicular occlusive disease that involves the intertriginous areas. Treatment methods include conventional topical and systemic medication, radiotherapy, biologic agents, and surgical excision. Of late, there has been an increased focus on the use of biologic agents in patients with moderate to severe HS. Here, we present the case of a 46-year-old man with Hurley stage III HS for whom wide excision was ultimately curative, after aggressive medical therapy with the use of infliximab and adalimumab had succeeded in limiting the body surface area affected by the disease. This case demonstrates the effective treatment of severe HS with a combination of biologic therapy and surgery.<\/jats:p>","DOI":"10.5999\/aps.2018.00339","type":"journal-article","created":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T08:23:38Z","timestamp":1555662218000},"page":"272-276","update-policy":"https:\/\/doi.org\/10.5999\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Management of severe hidradenitis suppurativa with biologic therapy and wide excision"],"prefix":"10.1055","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7079-2416","authenticated-orcid":false,"given":"Shi Yu Derek","family":"Lim","sequence":"additional","affiliation":[{"name":"National Healthcare Group, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4897-4029","authenticated-orcid":false,"given":"Ee Cherk","family":"Cheong","sequence":"additional","affiliation":[{"name":"Plastic, Reconstructive and Aesthetic Surgery Service, Department of General Surgery, Tan Tock Seng Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7607-3124","authenticated-orcid":false,"given":"Hazel H.","family":"Oon","sequence":"additional","affiliation":[{"name":"National Skin Centre, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2022,3,28]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1365-4632.2004.02536.x","article-title":"\u201cHidradenitis suppurativa\u201d is acne inversa! An appeal to (finally) abandon a misnomer","volume":"44","author":"K Sellheyer","year":"2005","journal-title":"Int J Dermatol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jdv.12966","article-title":"European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa","volume":"29","author":"CC Zouboulis","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use","volume":"19","author":"AY Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11154-016-9328-5","article-title":"Evidence-based approach to the treatment of hidradenitis suppurativa\/acne inversa, based on the European guidelines for hidradenitis suppurativa","volume":"17","author":"W Gulliver","year":"2016","journal-title":"Rev Endocr Metab Disord"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"AB Kimball","year":"2016","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2018.05.040","article-title":"Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa\/acne inversa: 3-year results of a phase 3 open-label extension study","volume":"80","author":"CC Zouboulis","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaad.2009.06.050","article-title":"Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial","volume":"62","author":"A Grant","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/jdv.13216","article-title":"HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study","volume":"30","author":"AB Kimball","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/bjd.14338","article-title":"Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum","volume":"174","author":"JL Blok","year":"2016","journal-title":"Br J Dermatol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jamadermatol.2015.3903","article-title":"Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial","volume":"152","author":"V Tzanetakou","year":"2016","journal-title":"JAMA Dermatol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jaad.2013.09.044","article-title":"An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa","volume":"70","author":"KS Leslie","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/jamadermatol.2017.2392","article-title":"Canakinumab for severe hidradenitis suppurativa: preliminary experience in 2 cases","volume":"153","author":"C Houriet","year":"2017","journal-title":"JAMA Dermatol"},{"key":"ref13","first-page":"36","article-title":"Non-response to interleukin-1 antagonist canakinumab in two patients with refractory pyoderma gangrenosum and hidradenitis suppurativa","volume":"10","author":"NZ Sun","year":"2017","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/13543784.2018.1412430","article-title":"Investigational drugs in clinical trials for hidradenitis suppurativa","volume":"27","author":"P Theut Riis","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jaad.2015.06.004","article-title":"To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis","volume":"73","author":"CS Ahn","year":"2015","journal-title":"J Am Acad Dermatol"}],"container-title":["Archives of Plastic Surgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-aps.org\/upload\/pdf\/aps-2018-00339.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-aps.org\/journal\/view.php?doi=10.5999\/aps.2018.00339","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.5999\/aps.2018.00339.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T09:05:58Z","timestamp":1705568758000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.5999\/aps.2018.00339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":15,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2022,3,28]]},"published-print":{"date-parts":[[2019,5]]}},"URL":"https:\/\/doi.org\/10.5999\/aps.2018.00339","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2234-6163","2234-6171"],"issn-type":[{"value":"2234-6163","type":"print"},{"value":"2234-6171","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"2018-03-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-20","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-15","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}